Fluoroquinolone-resistant Escherichia coli among the rectal flora is the predominant risk factor for severe infection after transrectal ultrasound-guided prostate biopsy: a prospective observational study
DOI:
https://doi.org/10.2340/sju.v58.11920Keywords:
transrectal ultrasound-guided prostate biopsy (TRUS-Bx), E. coli, Risk factors, fluoroquinolone-resistant (FQ-R) E. coli, urinary tract infection (UTI), postbiopsy infectionAbstract
Background: Infection of the prostate gland following biopsy, usually with Escherichia coli, is a common complication, despite the use of antimicrobial prophylaxis. A fluoroquinolone (FQ) is commonly prescribed as prophylaxis. Worryingly, the rate of fluoroquinolone-resistant (FQ-R) E. coli species has been shown to be increasing.
Objective: This study aimed to identify risk factors associated with infection after transrectal ultrasound-guided prostate biopsy (TRUS-Bx).
Methods: This was a prospective study on patients undergoing TRUS-Bx in southeast Sweden. Prebiopsy rectal and urine cultures were obtained, and antimicrobial susceptibility and risk-group stratification were determined. Multivariate analyses were performed to identify independent risk factors for post-biopsy urinary tract infection (UTI) and FQ-R E. coli in the rectal flora.
Results: In all, 283 patients were included, of whom 18 (6.4%) developed post-TRUS-Bx UTIs. Of these, 10 (3.5%) had an UTI without systemic inflammatory response syndrome (SIRS) and 8 (2.8%) had a UTI with SIRS. Being in the medium- or high-risk groups of infectious complications was not an independent risk factor for UTI with SIRS after TRUS-Bx, but low-level FQ-resistance (minimum inhibitory concentration (MIC): 0.125–0.25 mg/L) or FQ-resistance (MIC > 0.5 mg/L) among E. coli in the faecal flora was. Risk for SIRS increased in parallel with increasing degrees of FQ-resistance. Significant risk factor for harbouring FQ-R E.coli was travelling outside Europe within the previous 12 months.
Conclusion: The predominant risk factor for UTI with SIRS after TRUS-Bx was FQ-R E. coli among the faecal flora. The difficulty in identifying this type of risk factor demonstrates a need for studies on the development of a general approach either with rectal swab culture for targeted prophylaxis, or prior rectal preparation with a bactericidal agent such as povidone-iodine before TRUS-Bx to reduce the risk of FQ-R E. coli-related infection.
Downloads
References
Forsvall A, Jonsson H, Wagenius M, Bratt O, Linder A. Rate and characteristics of infection after transrectal prostate biopsy: a retrospective observational study. Scand J Urol. 2021;55(4):317–23. https://doi.org/10.1080/21681805.2021.1933169 DOI: https://doi.org/10.1080/21681805.2021.1933169
Zani EL, Clark OA, Rodrigues Netto N, Jr. Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev. 2011(5):CD006576. https://doi.org/10.1002/14651858.CD006576.pub2 DOI: https://doi.org/10.1002/14651858.CD006576.pub2
Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64(6):876–92. https://doi.org/10.1016/j.eururo.2013.05.049 DOI: https://doi.org/10.1016/j.eururo.2013.05.049
Liss MA, Ehdaie B, Loeb S, et al. An update of the American Urological Association white paper on the prevention and treatment of the more common complications related to prostate biopsy. J Urol. 2017;198(2):329–34. https://doi.org/10.1016/j.juro.2017.01.103 DOI: https://doi.org/10.1016/j.juro.2017.01.103
Bennett HY, Roberts MJ, Doi SA, Gardiner RA. The global burden of major infectious complications following prostate biopsy. Epidemiol Infect. 2016;144(8):1784–91. https://doi.org/10.1017/S0950268815002885 DOI: https://doi.org/10.1017/S0950268815002885
Steensels D, Slabbaert K, De Wever L, Vermeersch P, Van Poppel H, Verhaegen J. Fluoroquinolone-resistant E. coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy – should we reassess our practices for antibiotic prophylaxis? Clin Microbiol Infect. 2012;18(6):575–81. https://doi.org/10.1111/j.1469-0691.2011.03638.x DOI: https://doi.org/10.1111/j.1469-0691.2011.03638.x
Scott S, Harris PN, Williamson DA, Liss MA, Doi SAR, Roberts MJ. The effectiveness of targeted relative to empiric prophylaxis on infectious complications after transrectal ultrasound-guided prostate biopsy: a meta-analysis. World J Urol. 2018;36(7):1007–17. https://doi.org/10.1007/s00345-018-2217-7 DOI: https://doi.org/10.1007/s00345-018-2217-7
The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 10.0, 2020. Available from: http://www.eucast.org/clinical_breakpoints/ [cited 20 October 2022].
Kalalahti I, Huotari K, Lahdensuo K, et al. Rectal E. coli above ciprofloxacin ECOFF associate with infectious complications following prostate biopsy. Eur J Clin Microbiol Infect Dis. 2018;37(6):1055–60. https://doi.org/10.1007/s10096-018-3217-7 DOI: https://doi.org/10.1007/s10096-018-3217-7
Boeri L, Fontana M, Gallioli A, et al. Rectal culture-guided targeted antimicrobial prophylaxis reduces the incidence of post-operative infectious complications in men at high risk for infections submitted to transrectal ultrasound prostate biopsy – results of a cross-sectional study. PLoS One. 2017;12(1):e0170319. https://doi.org/10.1371/journal.pone.0170319 DOI: https://doi.org/10.1371/journal.pone.0170319
Eruz ED, Yalci A, Ozden E, et al. Risk factors for infection development after transrectal prostate biopsy and the role of resistant bacteria in colonic flora. J Infect Dev Ctries. 2017;11(2):188–91. https://doi.org/10.3855/jidc.7067 DOI: https://doi.org/10.3855/jidc.7067
Hamarat MB, Tarhan F, Horuz R, et al. Infective complications in patients after transrectal ultrasound-guided prostate biopsy and the role of ciprofloxacin resistant Escherichia coli colonization in rectal flora. Turk J Urol. 2017;43(2):210–5. https://doi.org/10.5152/tud.2017.76390 DOI: https://doi.org/10.5152/tud.2017.76390
Liss MA, Taylor SA, Batura D, et al. Fluoroquinolone resistant rectal colonization predicts risk of infectious complications after transrectal prostate biopsy. J Urol. 2014;192(6):1673–8. https://doi.org/10.1016/j.juro.2014.06.005 DOI: https://doi.org/10.1016/j.juro.2014.06.005
Taylor AK, Zembower TR, Nadler RB, et al. Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. J Urol. 2012;187(4):1275–9. https://doi.org/10.1016/j.juro.2011.11.115 DOI: https://doi.org/10.1016/j.juro.2011.11.115
Adamczyk P, Juszczak K, Prondzinska M, Kedzierska A, Szwajkert-Sobiecka H, Drewa T. Fluoroquinolone-resistant Escherichia coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy – possible shift in biopsy prophylaxis. Cent European J Urol. 2017;70(2):192–6. https://doi.org/10.5173/ceju.2017.739 DOI: https://doi.org/10.5173/ceju.2017.739
Aly M, Dyrdak R, Nordstrom T, et al. Rapid increase in multidrug-resistant enteric bacilli blood stream infection after prostate biopsy – a 10-year population-based cohort study. Prostate. 2015;75(9):947–56. https://doi.org/10.1002/pros.22979 DOI: https://doi.org/10.1002/pros.22979
de Jesus CM, Correa LA, Padovani CR. Complications and risk factors in transrectal ultrasound-guided prostate biopsies. Sao Paulo Med J. 2006;124(4):198–202. https://doi.org/10.1590/S1516-31802006000400005 DOI: https://doi.org/10.1590/S1516-31802006000400005
Ljungquist O, Persmark A, Grabe M, et al. Increasing rates of urinary and bloodstream infections following transrectal prostate biopsy in South Sweden. BJU Int. 2022;130(4):478–85. https://doi.org/10.1111/bju.15713 DOI: https://doi.org/10.1111/bju.15713
Zaytoun OM, Vargo EH, Rajan R, Berglund R, Gordon S, Jones JS. Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology. 2011;77(5):1035–41. https://doi.org/10.1016/j.urology.2010.12.067 DOI: https://doi.org/10.1016/j.urology.2010.12.067
Lundstrom KJ, Drevin L, Carlsson S, et al. Nationwide population based study of infections after transrectal ultrasound guided prostate biopsy. J Urol. 2014;192(4):1116–22. https://doi.org/10.1016/j.juro.2014.04.098 DOI: https://doi.org/10.1016/j.juro.2014.04.098
Kandemir O, Bozlu M, Efesoy O, Guntekin O, Tek M, Akbay E. The incidence and risk factors of resistant E. coli infections after prostate biopsy under fluoroquinolone prophylaxis: a single-centre experience with 2215 patients. J Chemother. 2016;28(4):284–8. https://doi.org/10.1179/1973947815Y.0000000001 DOI: https://doi.org/10.1179/1973947815Y.0000000001
Kisa E, Altug MU, Gurbuz OA, Ozdemir H. Fosfomycin: a good alternative drug for prostate biopsy prophylaxis the results of a prospective, randomized trial with respect to risk factors. Int Braz J Urol. 2017;43(6):1068–74. https://doi.org/10.1590/s1677-5538.ibju.2016.0619 DOI: https://doi.org/10.1590/s1677-5538.ibju.2016.0619
Holmbom M, Moller V, Nilsson LE, et al. Low incidence of antibiotic-resistant bacteria in south-east Sweden: an epidemiologic study on 9268 cases of bloodstream infection. PLoS One. 2020;15(3):e0230501. https://doi.org/10.1371/journal.pone.0230501 DOI: https://doi.org/10.1371/journal.pone.0230501
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Martin Holmbom, Jon Forsberg, Mats Fredrikson, Maud Nilsson, Lennart E. Nilsson, Håkan Hanberger, Anita Hällgren
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Acta Chirurgica Scandinavica Society owns the copyright for all material published until Volume 57 (2023) unless otherwise specified. As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
